Outset Medical, Inc. (OM)
After hours:
| Previous close | 2.5500 |
| Open | 2.4700 |
| Bid | 2.3600 x 600 |
| Ask | 2.4100 x 400 |
| Day's range | 2.2950 - 2.4720 |
| 52-week range | 1.9200 - 24.1300 |
| Volume | |
| Avg. volume | 972,520 |
| Market cap | 123.051M |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.4800 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.79 |
Business WireOutset Medical to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
SAN JOSE, Calif., April 19, 2024--Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024.
ZacksOutset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.
Business WireOutset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.
SAN JOSE, Calif., April 17, 2024--Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced today a multi-year agreement to help accelerate home hemodialysis in the U.S.
